Cadmus Rich has joined Aura Biosciences to become the Cambridge, MA, company’s chief medical officer. Rich most recently worked at Inotek Pharmaceuticals (NASDAQ: [[ticker:ITEK]]) in Lexington, MA, where he was vice president, medical affairs and clinical development. Aura’s lead drug, AU-11, is in early-stage clinical testing for ocular melanoma, a rare eye cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
